CASI Pharmaceuticals appoints new president for China Operations

CASI Pharmaceuticals, a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces the appointment of Larry Zhang to the position of President of CASI (Beijing) Pharmaceuticals Co., Ltd., the China operating subsidiary of CASI Pharmaceuticals, Inc. headquartered in Rockville, Maryland.

Zhang possesses over 20 years of executive experience in commercial operations, regulatory affairs, sales and marketing, and business development within the healthcare and biopharmaceutical industries in the U.S., Asia Pacificand China. Prior to joining CASI's Beijing office, Mr. Zhang was Vice President, Head of Public Affairs and Corporate Responsibility at Novartis Group (China) focusing on the public affairs and public relations strategy including initiating Novartis' China policy focusing on China FDA (CFDA) new drug approval reform, IP protection, generic quality consistency evaluation and new regulations on biosimilars. In this role, he regularly liaised with key central and provisional government authorities to advance various policy initiatives.

Prior to joining Novartis Group (China), he served as Chief Executive Officer of Sandoz (China) Pharmaceutical Co. Ltd, a Novartis Company, where he oversaw the successful launch of six new products. Mr. Zhang has also held executive leadership roles within Bayer Healthcare and Baxter International Corporation in the U.S. and Asia Pacific. He holds bachelor and master's degrees in nuclear physics from the University of Science & Technology of China, and an M.B.A. in marketing/finance from the University of California at Los Angeles (UCLA). He also received training in the political science doctoral program from the University of Utah. 

Wei-Wu He, Ph.D., Executive Chairman of CASI Pharmaceuticals, commented, "We are excited to welcome Larry to our management team. His cross-functional executive expertise, particularly in navigating CFDA reforms and governmental affairs within the generic pharmaceuticals sector, will be invaluable to CASI's advancement and growth as we continue to expand and advance our pipeline."